MS therapeutics market led by Copaxone

The multiple sclerosis (MS) therapeutics market has been forecast to increase at a compound annual growth rate (CAGR) of 11.6% over the next six years, increasing from a value of $8.1 billion in 2012, to reach a value of $17.6 billion by 2019, according to a new report added to the offering of Companiesandmarkets.com

Several therapies for multiple sclerosis exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).

The most common initial course of the disease is the relapsing-remitting subtype, which is characterised by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis.